
Meagan Myers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/193356/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia. Toxicological Sciences, 2021, 182, 142-158.	3.1	3
2	Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia. Toxicological Sciences, 2021, 184, 1-14.	3.1	1
3	Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk. Environmental and Molecular Mutagenesis, 2020, 61, 152-175.	2.2	13
4	Quantification of cancer driver mutations in human breast and lung <scp>DNA</scp> using targeted, errorâ€corrected <scp>CarcSeq</scp> . Environmental and Molecular Mutagenesis, 2020, 61, 872-889.	2.2	6
5	Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids. PLoS ONE, 2020, 15, e0238862.	2.5	12
6	Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology. International Journal of Molecular Sciences, 2019, 20, 1011.	4.1	8
7	Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium. Cell Stem Cell, 2018, 22, 909-918.e8.	11.1	89
8	Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status. Reproductive Toxicology, 2017, 69, 187-195.	2.9	10
9	Dose and temporal evaluation of ethylene oxideâ€induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations. Environmental and Molecular Mutagenesis, 2017, 58, 122-134.	2.2	10
10	Variation in organâ€specific <i>PIK3CA</i> and <i>KRAS</i> mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. Environmental and Molecular Mutagenesis, 2017, 58, 466-476.	2.2	16
11	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives. Pharmacogenomics and Personalized Medicine, 2016, 9, 7.	0.7	20
12	Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas. Neoplasia, 2016, 18, 253-263.	5.3	37
13	Low-frequency <i>KRAS</i> mutations are prevalent in lung adenocarcinomas. Personalized Medicine, 2015, 12, 83-98.	1.5	19
14	A subset of papillary thyroid carcinomas contain <i>KRAS</i> mutant subpopulations at levels above normal thyroid. Molecular Carcinogenesis, 2014, 53, 159-167.	2.7	22
15	<i>KRAS</i> mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. Personalized Medicine, 2013, 10, 191-199.	1.5	19
16	Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide. Toxicological Sciences, 2013, 136, 26-38.	3.1	22
17	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	3.1	13
18	ACBâ€PCR measurement of Hâ€ <i>ras</i> codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. Environmental and Molecular Mutagenesis, 2012, 53, 495-504.	2.2	22